News

For a year and a half, the Council of the European Union has been unable to reach an agreement on the deregulation of GMOs, mainly because of the problems posed by patents on those GMOs or on the techniques used to obtain them. According to Copa-Cogeca, those two issues should be dealt with separately. Its proposal is to adopt the deregulation of GMOs as quickly as possible and postpone the study of the problem posed by patents. Even if it means forgetting that farmers are indeed affected by patents.

At a time when the European Union is preparing new regulations on seeds, a look at the meetings between MEPs and the various stakeholders indirectly shows the weight of the multinationals in these procedures. This raises questions about the imbalance in the representation of these parties and the potential consequences for small seed companies, farmers and peasants.

Can biological diversity escape any risk of biopiracy when part of it is digitised in computers? The answer depends on ongoing negotiations within international bodies. In the meantime, an international project to sequence the genome of all known eukaryotic species is making progress. Financed indirectly by players in the IT and artificial intelligence fields, this project even hopes to be able to bypass certain rules thanks to more powerful working tools.

The Svalbard Global Seed Vault (Svalbard, Norway), often nicknamed the “seed vault”, plays a special role in preserving genetic biodiversity. Its main mission, focused on the long-term conservation of seed samples, is officially to preserve the diversity of plant genetic resources and ensure their accessibility in the event of disasters. However, a closer look at how it works reveals the considerable influence and interests of pro-GMO players in its governance. Who will really benefit from Svalbard, the multinationals or the farmers?

Mon810 maize is the only transgenic GM plant authorized for commercial cultivation in the European Union. This authorization was initially granted, via France, almost 30 years ago, in 1998, for an initial period of 10 years. A renewal application was submitted in 2007. Since then, no decision has been taken by the European authorities. How this maize, which authorization theoretically expired in 2008, can still be grown legally in Europe? Simply because European law accepts that, as long as the European Commission has not responded to a request for renewal, the initial authorization remains valid. To date, it’s been 15 years that the Commission fails to respond to Bayer/Monsanto’s request.

On 15 October 2024, the European Patent Office (EPO) upheld KWS’s patent for cold-resistant maize. This decision is likely to raise serious concerns among European seed breeders, who may now feel threatened in their breeding work. The patent covers maize plants containing a naturally occurring genetic sequence, which restricts the freedom of breeders to develop new varieties. The “oral proceedings”, which took place before the EPO Opposition Division and which Inf’OGM attended by video-conference, gave rise to some unusual and revealing exchanges. This case shows once again that patents can indeed be tools for appropriating seeds developed by farmers and/or breeders.

In less than a year and a half, from May 3, 2022 to October 12, 2023, the previous European Commission has launched a number of legislative initiatives concerning the Living. The deregulation of GMOs, the digitization of living organisms and even patents are just some of the issues on the table of member states and the European Parliament. If adopted, these projects will make it easier for companies with substantial financial, human and technical resources to take ownership of the Living. These initiatives do echo current international negotiations.

Understanding the absence of any obligation to disclose the origin of the material on which a patented “invention” is based is one of the keys to understanding the ongoing strategy of appropriation of living organisms by a few multinationals. In the field of patents, Inf’OGM has chosen to publish an article shedding light on a […]

After genetic sequences and DNA, here comes RNA, the new flagship molecule in biotechnology that is supposed to solve agricultural and health problems. Companies in this field are flourishing. Among them is GreenLight Biosciences, a company that was on the verge of bankruptcy when it was bought by the investment fund Fall Line Capital.